ABIVAX abstract on ABX464 selected for presentation at the AIDS 2016 Conference in Durban, South Africa
ABIVAX abstract on ABX464 selected for presentation at the AIDS 2016 Conference in Durban, South Africa
April 27, 2016
- Details
- Published on Wednesday, 27 April 2016 18:00
Paris, April 27th, 2016 - ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its abstract entitled, “Antiviral activity and safety of ABX464 in HIV-infected treatment-naïve patients” has been selected for presentation at the 21st International AIDS Conference (AIDS 2016) to be held in Durban, South Africa, 18-22 July 2016. The date and time of the presentation will be communicated in the coming weeks.